The race to build a truly universal CAR-T cell therapy just got a lot more interesting.
AvenCell Therapeutics dosed the first patient in its Phase I QUADvance study evaluating AVC-203. This is their allogeneic CAR-T that simultaneously targets CD19 and CD20 in relapsed/refractory B-cell malignancies, including DLBCL.
But here’s what makes this one different from the dozen other allogeneic CAR-T plays you’ve seen cross your feed: AVC-203 is built on AvenCell’s proprietary RevCAR switchable receptor technology.
The constitutive dual-targeting handles CD19/CD20 out of the box, but the RevCAR component is designed to bolt on additional targets later via bi- or tri-specific bridging proteins. One cell therapy. Multiple cancers. That’s the pitch.
The timing here is actually really interesting.
Gilead just dropped $7.8 billion to acquire Arcellx and its ARC-SparX platform — another switchable/controllable CAR-T system that pairs universal ARC-T cells with dosable SparX proteins.
That deal validated the entire category of programmable cell therapies in a way that no Phase 1 press release ever could. AvenCell is now walking into a clinic where the market has already said: yes, we believe in this.
How RevCAR switchable CAR-T works
Allogeneic T-Cell
→
Universal Receptor
→
(CD19/CD20 today)
→
Killed
Future bridging proteins can redirect the same T-cells to new targets — no re-engineering required
AvenCell isn’t new to the allogeneic game either.
The company already has Allo-RevCAR01-T in a Phase 1 study targeting CD123 in relapsed/refractory AML…a completely different indication, same switchable chassis.
That’s the platform thesis in action.
And it’s worth noting that AVC-203 is being described as the first CRISPR-engineered allogeneic dual-targeting switchable CAR-T to enter clinical testing. That’s a mouthful, but it’s also a first.
The big question, as always with allogeneic approaches: will the off-the-shelf cells persist long enough to matter?
Autologous CAR-T has the durability advantage, and Gilead’s Arcellx bet was on autologous D-Domain cells, not allogeneic. AvenCell is betting that CRISPR engineering plus the flexibility of a switchable system can close that gap.
No data yet – after all, this is first-patient-dosed territory – but the architecture is compelling, and the competitive validation is already in the bank.
The Biotech Voyager
Early-stage biotech signals, personalized.
The signals that matter to you — contextualized and written directly to you — so you cut through the noise and immediately understand why it matters.
